With thousands of companies and a $102 billion impact on the state’s economy, Indiana’s life sciences industry is making its ...

Besting Vertex Pharmaceuticals’ kidney disease asset wasn’t enough to impress Wall Street, which appears to be “getting hung ...

In vivo CAR-T has attracted significant attention from venture capital and the pharmaceutical industry. By offering the ...

This year's catalysts in the space include a near-term FDA decision on Eli Lilly’s oral challenger to the new Wegovy pill.

Looking for a biopharma job in New York? Check out the BioSpace list of 11 companies hiring life sciences professionals like ...

Missing one of its co-primary endpoints could make it difficult for Karyopharm Therapeutics to score conventional approval ...

While RA Capital Management has yet to commit to a merger plan, it noted that its new blank-check company, Research Alliance ...

Gilead continues its dealmaking spree in the sizzling hot space of I&I as Johnson & Johnson, along with partner Protagonist, ...

Overall, the top 16 largest pharmaceutical companies spent $159 billion on research and development in 2025, compared to $165 ...

Trace Neuroscience, a member of BioSpace’s NextGen Class of 2026, has learned from the success of Biogen’s Qalsody and aims ...

While ersodetug missed the Phase 3 primary endpoint of a reduction in hypoglycemia events, Rezolute argued that this goal was ...

Draft guidance, issued by the FDA last week, could remove ambiguity and uncertainty that may have so far limited uptake of ...